motor fluctuations Archives

Conceptual Serina Therapeutics illustration featuring molecular structures, a drug-delivery particle, neurons, a glowing brain and the SER stock ticker

Serina Therapeutics’ Parkinson’s Opportunity: A Proven Molecule, Smarter Delivery and an Emerging Clinical Case -( $SER $IBB $XBI )

by John F. Heerdink, Jr. 6 hours ago 63Views 0Likes

Serina's SER-252 Puts a Practical Innovation at the Center of the Story Biotechnology often commands attention by promising an entirely new molecule. Serina Therapeutics (NYSE American: SER) is pursuing a different proposition: take an established therapeutic agent, improve how it reaches the patient and…

Comic-style illustration of Michael J. Fox pointing toward a glowing brain, alongside Parkinson’s research labs, medicines and rising stock-market arrows.

Parkinson’s Drug Stocks Enter a New Chapter as Michael J. Fox’s Mission Meets Medical Momentum -( $ABBV $IBB $SER $SUPN $XBI )

by John F. Heerdink, Jr. November 2, 2026 444Views 0Likes

Michael J. Fox’s promotion to Companion of the Order of Canada on October 2, 2026, recognized a remarkable transformation: a celebrated actor had become one of the world’s most consequential advocates for Parkinson’s research. His foundation, established in 2000, has funded approximately…

Conceptual Serina Therapeutics laboratory illustration with neurons, drug-delivery imagery and a display highlighting a potential 2027 clinical milestone.

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

by John F. Heerdink, Jr. October 26, 2026 280Views 0Likes

As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself. Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 608Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

by John F. Heerdink, Jr. September 9, 2026 560Views 0Likes

Serina Therapeutics, Inc. (NYSE American: SER) has moved its lead Parkinson’s disease program from promise on paper to progress in patients. After an independent safety committee completed its blinded review of the first cohort in the Company’s Phase 1b registrational study, Serina received…

Tag: motor fluctuations

Serina Therapeutics’ Parkinson’s Opportunity: A Proven Molecule, Smarter Delivery and an Emerging Clinical Case -( $SER $IBB $XBI )

Parkinson’s Drug Stocks Enter a New Chapter as Michael J. Fox’s Mission Meets Medical Momentum -( $ABBV $IBB $SER $SUPN $XBI )

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Clears a Key Parkinson’s Hurdle -( $PFE $SER $XBI )

Your Guide To Staying Informed In The Markets